Clinical Trial Detail

NCT ID NCT03546361
Title Intratumoral Administration of CCL21-gene Modified Dendritic Cell With Intravenous Pembrolizumab for Advanced NSCLC
Recruitment Recruiting
Gender both
Phase Phase I
Variant Requirements No
Sponsors Jonsson Comprehensive Cancer Center
Indications

lung non-small cell carcinoma

Therapies

Ad-CCL21-DC

Ad-CCL21-DC + Pembrolizumab

Age Groups: adult senior

No variant requirements are available.